EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access

VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection

Thomas Louie, Yoav Golan, Sahil Khanna, Dmitri Bobilev, Nathalie Erpelding, Candida Fratazzi, Meg Carini, Rajita Menon, Mary Ruisi, Jason M Norman, Jeremiah J Faith, Bernat Olle und 3 weitere

JAMA · 25.04.2023 · 329 (16) · 1356

DOI: 10.1001/jama.2023.4314 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JAMA, erschienen am 25.04.2023. Verfasst von Thomas Louie und 14 weiteren Autor:innen. Beteiligte Einrichtung: University of Calgary and Foothills Medical Centre, Calgary, Alberta, Canada. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections, Probiotics. Die Arbeit wurde bisher 224-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The effect of rationally defined nonpathogenic, nontoxigenic, commensal strains of Clostridia on prevention of Clostridioides difficile infection (CDI) is unknown.

Objective

To determine the efficacy of VE303, a defined bacterial consortium of 8 strains of commensal Clostridia, in adults at high risk for CDI recurrence. The primary objective was to determine the recommended VE303 dosing for a phase 3 trial. Design, Setting, and Participants Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study conducted from February 2019 to September 2021 at 27 sites in the US and Canada. The study included 79 participants aged 18 years or older who were diagnosed with laboratory-confirmed CDI with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence (defined as aged ≥75 years or ≥65 years with ≥1 risk factors: creatinine clearance <60 mL/min/1.73 m 2 , proton pump inhibitor use, remote [>6 months earlier] CDI history).

Interventions

Participants were randomly assigned to high-dose VE303 (8.0 × 10 9 colony-forming units [CFUs]) (n = 30), low-dose VE303 (1.6 × 10 9 CFUs) (n = 27), or placebo capsules (n = 22) orally once daily for 14 days. Main Outcomes and Measures The primary efficacy end point was the proportion of participants with CDI recurrence at 8 weeks using a combined clinical and laboratory definition. The primary efficacy end point was analyzed in 3 prespecified analyses, using successively broader definitions for an on-study CDI recurrence: (1) diarrhea consistent with CDI plus a toxin-positive stool sample; (2) diarrhea consistent with CDI plus a toxin-positive, polymerase chain reaction–positive, or toxigenic culture–positive stool sample; and (3) diarrhea consistent with CDI plus laboratory confirmation or (in the absence of a stool sample) treatment with a CDI-targeted antibiotic.

Results

Baseline characteristics were similar across the high-dose VE303 (n = 29; 1 additional participant excluded from efficacy analysis), low-dose VE303 (n = 27), and placebo (n = 22) groups. The participants’ median age was 63.5 years (range, 24-96); 70.5% were female; and 1.3% were Asian, 1.3% Black, 2.6% Hispanic, and 96.2% White. CDI recurrence rates through week 8 (using the efficacy analysis 3 definition) were 13.8% (4/29) for high-dose VE303, 37.0% (10/27) for low-dose VE303, and 45.5% (10/22) for placebo ( P = .006, high-dose VE303 vs placebo). Conclusions and Relevance Among adults with laboratory-confirmed CDI with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence, high-dose VE303 prevented recurrent CDI compared with placebo. A larger, phase 3 study is needed to confirm these findings. Trial Registration ClinicalTrials.gov Identifier: NCT03788434

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridioides difficileClostridium InfectionsProbioticsAdultFemaleHumansMaleMiddle AgedAnti-Bacterial AgentsDiarrheaFecesGastrointestinal MicrobiomeRecurrenceReinfectionSymbiosisTreatment OutcomeDouble-Blind MethodBacterial ToxinsYoung AdultAgedAged, 80 and over

Substanzen

Anti-Bacterial AgentsBacterial Toxins

Autor:innen und Institutionen

  • University of Calgary and Foothills Medical Centre, Calgary, Alberta, Canada.
  • Tufts Medical Center, Boston, Massachusetts.
  • Mayo Clinic, Rochester, Minnesota.
  • Vedanta Biosciences Inc, Cambridge, Massachusetts.
  • Fusion Pharmaceuticals, Boston, Massachusetts.
  • Bicycle Therapeutics, Cambridge, Massachusetts.

Zitieren

APA

Louie, T., Golan, Y., Khanna, S., Bobilev, D., Erpelding, N., Fratazzi, C., Carini, M., Menon, R., Ruisi, M., Norman, J. M., Faith, J. J., Olle, B., Li, M., Silber, J. L., & Pardi, D. S. (2023). VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection. JAMA, 329(16), 1356. https://doi.org/10.1001/jama.2023.4314

Vancouver

Louie T, Golan Y, Khanna S, Bobilev D, Erpelding N, Fratazzi C, et al. VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection. JAMA. 2023;329(16):1356. doi:10.1001/jama.2023.4314

BibTeX
@article{Louie2023,
  author = {Louie, Thomas and Golan, Yoav and Khanna, Sahil and Bobilev, Dmitri and Erpelding, Nathalie and Fratazzi, Candida and Carini, Meg and Menon, Rajita and Ruisi, Mary and Norman, Jason M and Faith, Jeremiah J and Olle, Bernat and Li, Minran and Silber, Jeffrey L and Pardi, Darrell S},
  title = {VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection},
  journal = {JAMA},
  year = {2023},
  volume = {329},
  number = {16},
  pages = {1356},
  doi = {10.1001/jama.2023.4314}
}
Kostenlos starten →